https://www.selleckchem.com/pr....oducts/apr-246-prima
However, there were less hypoglycemic events and weight gain in the DPP4 inhibitor group as compared with the SU group (random-effect RR, 3.79; 95% CI, 1.53-9.39; 0.001; I =98.2 and weighted mean difference, 1.68; 95% CI, 1.07-2.29; 0.001; I =94.7, respectively). As add-on therapy to metformin, there were no significant differences in all-cause mortality and cardiovascular mortality between DPP4 inhibitors and SUs. As add-on therapy to metformin, there were no significant differences in all-cause mortality and cardiov
Like
Comment
Share
